| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Evaluation of a combined triple method to detect causative HPV in oral and oropharyngeal squamous cell carcinomas: p16 Immunohistochemistry, Consensus PCR HPV-DNA, and In Situ Hybridization.
|
Infect Agent Cancer
|
2012
|
1.17
|
|
2
|
Translating tumor antigens into cancer vaccines.
|
Clin Vaccine Immunol
|
2010
|
1.09
|
|
3
|
Molecular signatures associated with HCV-induced hepatocellular carcinoma and liver metastasis.
|
PLoS One
|
2013
|
1.06
|
|
4
|
Update on Head and Neck Cancer: Current Knowledge on Epidemiology, Risk Factors, Molecular Features and Novel Therapies.
|
Oncology
|
2015
|
1.03
|
|
5
|
Effects of adjuvants on IgG subclasses elicited by virus-like particles.
|
J Transl Med
|
2012
|
0.99
|
|
6
|
Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation.
|
J Transl Med
|
2005
|
0.98
|
|
7
|
Challenges in cancer vaccine development for hepatocellular carcinoma.
|
J Hepatol
|
2013
|
0.95
|
|
8
|
Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation.
|
BMC Bioinformatics
|
2008
|
0.92
|
|
9
|
Developments in virus-like particle-based vaccines for infectious diseases and cancer.
|
Expert Rev Vaccines
|
2011
|
0.91
|
|
10
|
Virus-like particle vaccines and adjuvants: the HPV paradigm.
|
Expert Rev Vaccines
|
2009
|
0.91
|
|
11
|
Antigen-specific vaccines for cancer treatment.
|
Hum Vaccin Immunother
|
2014
|
0.89
|
|
12
|
Screening of HIV-1 isolates by reverse heteroduplex mobility assay and identification of non-B subtypes in Italy.
|
J Acquir Immune Defic Syndr
|
2004
|
0.89
|
|
13
|
TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients.
|
Infect Agent Cancer
|
2011
|
0.87
|
|
14
|
Kaposi's sarcoma: etiology and pathogenesis, inducing factors, causal associations, and treatments: facts and controversies.
|
Clin Dermatol
|
2013
|
0.87
|
|
15
|
Systems biology applied to vaccine and immunotherapy development.
|
BMC Syst Biol
|
2011
|
0.85
|
|
16
|
New adjuvants in evolving vaccine strategies.
|
Expert Opin Biol Ther
|
2011
|
0.83
|
|
17
|
VLPs and particle strategies for cancer vaccines.
|
Expert Rev Vaccines
|
2013
|
0.83
|
|
18
|
Molecular immune signatures of HIV-1 vaccines in human PBMCs.
|
FEBS Lett
|
2009
|
0.83
|
|
19
|
Genetic and phylogenetic evolution of HIV-1 in a low subtype heterogeneity epidemic: the Italian example.
|
Retrovirology
|
2007
|
0.82
|
|
20
|
Functional interaction between human papillomavirus type 16 E6 and E7 oncoproteins and cigarette smoke components in lung epithelial cells.
|
PLoS One
|
2012
|
0.82
|
|
21
|
Somatic mutations of STK11 gene in human papillomavirus positive and negative penile cancer.
|
Infect Agent Cancer
|
2013
|
0.82
|
|
22
|
TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix.
|
J Transl Med
|
2014
|
0.82
|
|
23
|
Molecular and phylogenetic analysis of HIV-1 variants circulating in Italy.
|
Infect Agent Cancer
|
2008
|
0.81
|
|
24
|
Characterization of the human papillomavirus (HPV) integration sites into genital cancers.
|
Pathol Oncol Res
|
2012
|
0.81
|
|
25
|
Molecular epidemiology of human herpesvirus 8 variants in Kaposi's sarcoma from Iranian patients.
|
Virus Res
|
2011
|
0.81
|
|
26
|
Immunogenicity of HIV virus-like particles in rhesus macaques by intranasal administration.
|
Clin Vaccine Immunol
|
2012
|
0.81
|
|
27
|
Innate immunity and hepatitis C virus infection: a microarray's view.
|
Infect Agent Cancer
|
2012
|
0.80
|
|
28
|
Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model.
|
Cancer Immunol Immunother
|
2015
|
0.80
|
|
29
|
Evaluation of a modified version of Heteroduplex Mobility Assay for rapid screening of HIV-1 isolates in epidemics characterized by mono/dual clade predominance.
|
J Virol Methods
|
2005
|
0.80
|
|
30
|
An overview of new biomolecular pathways in pathogen-related cancers.
|
Future Oncol
|
2015
|
0.79
|
|
31
|
HPV type distribution in invasive cervical cancers in Italy: pooled analysis of three large studies.
|
Infect Agent Cancer
|
2012
|
0.79
|
|
32
|
Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate.
|
J Transl Med
|
2013
|
0.78
|
|
33
|
Cellular prognostic markers in hepatocellular carcinoma.
|
Future Oncol
|
2015
|
0.78
|
|
34
|
Formation of self-assembled triple-layered rotavirus-like particles (tlRLPs) by constitutive co-expression of VP2, VP6, and VP7 in stably transfected high-five insect cell lines.
|
J Med Virol
|
2014
|
0.78
|
|
35
|
Developments in virus-like particle-based vaccines for HIV.
|
Expert Rev Vaccines
|
2013
|
0.78
|
|
36
|
Plant-based anti-HIV-1 strategies: vaccine molecules and antiviral approaches.
|
Expert Rev Vaccines
|
2010
|
0.77
|
|
37
|
HIV p24 as scaffold for presenting conformational HIV Env antigens.
|
PLoS One
|
2012
|
0.77
|
|
38
|
Prediction of individual immune responsiveness to a candidate vaccine by a systems vaccinology approach.
|
J Transl Med
|
2014
|
0.77
|
|
39
|
Multiparametric analyses of human PBMCs loaded ex vivo with a candidate idiotype vaccine for HCV-related lymphoproliferative disorders.
|
PLoS One
|
2012
|
0.77
|
|
40
|
Conformational HIV-1 envelope on particulate structures: a tool for chemokine coreceptor binding studies.
|
J Transl Med
|
2011
|
0.76
|
|
41
|
Assessment of Chlamydia trachomatis infection among Eastern European and West African women immigrants in South Italy.
|
Sex Transm Infect
|
2011
|
0.76
|
|
42
|
Can HIV p24 be a suitable scaffold for presenting Env antigens?
|
Clin Vaccine Immunol
|
2011
|
0.76
|
|
43
|
Oncolytic virus therapies.
|
Pharm Pat Anal
|
2012
|
0.75
|
|
44
|
Correction: Genetic Diversity of the KIR/HLA System and Susceptibility to Hepatitis C Virus-Related Diseases.
|
PLoS One
|
2015
|
0.75
|
|
45
|
An overview of Bioactive Peptides for in vivo Imaging and Therapy in Human Diseases.
|
Mini Rev Med Chem
|
2017
|
0.75
|
|
46
|
Foreword. Cancer biomarkers.
|
Future Oncol
|
2015
|
0.75
|
|
47
|
Unsung hero Robert C. Gallo.
|
Science
|
2009
|
0.75
|